This article was originally published in The Gray Sheet
Private placement of 42.2 mil. shares of common stock raises $12.7 mil. About 21.5 mil. five-year warrants also were issued in connection with the financing. Proceeds will be used for manufacturing and marketing of the firm's Posicam postitron emission tomography scanners, as well as debt repayment and general corporate purposes. The funding follows Imatron's January purchase of a controlling interest in Positron and is in line with Imatron's plans to reactivate and recapitalize the dormant PET maker (1"The Gray Sheet" Feb. 1, p. 15). The capital infusion comes on the heels of recent favorable reimbursement recommendations for a broad range of PET procedures from the Health Care Financing Administration (2"The Gray Sheet" March 15, p. 20)
You may also be interested in...
Medicare will cover three additional indications for positron emission tomography (PET) in the diagnosis and management of cancer, the Health Care Financing Administration announced March 8.
Imatron is looking to revitalize positron emission tomography scanner maker Positron Corporation following the firm's Jan. 25 purchase of 51%, or 9 mil. shares of Positron common stock.
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.